On this page

fluocinolone acetonide

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Fluocinolone Acetonide
Generic name
fluocinolone acetonide
Dosage form
Solution
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Fougera Pharmaceuticals, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
3
Packages
4
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Fluocinolone Acetonide .1 mg/mL 1191310 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Topical
Presentations
7

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
088167
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 16, 1982
Sponsor
FOUGERA PHARMS INC
Products on application
1
Submissions recorded
4
Products approved under application 088167.
Product Trade name Form Strength Ingredient Status TE Flags
088167-001 FLUOCINOLONE ACETONIDE SOLUTION FLUOCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 088167.
Type No. Action Status Date Review
Supplement 6 Labeling Approved April 11, 2005 —
Supplement 5 Manufacturing (CMC) Approved June 24, 1996 —
Supplement 3 Manufacturing (CMC) Approved March 9, 1988 —
Original application 1 Approved December 16, 1982 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260128). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260128 HUMAN PRESCRIPTION DRUG · 20250703 HUMAN PRESCRIPTION DRUG · 20190221

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Topical Solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

Description

openFDA Drug Labeling

DESCRIPTION Fluocinolone Acetonide Topical Solution USP, 0.01% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-,(6α,11β,16α)-. It has the following chemical structure: Fluocinolone Acetonide 0.01% Solution (each mL contains 0.1 mg Fluocinolone Acetonide) in a water-washable base containing citric acid and propylene glycol. Chemical Structure

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Fluocinolone Acetonide Topical Solution USP, 0.01% 60 cc Bottle with applicator tip – NDC 43386-069-60 STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc at 1-866-403-7592 or FDA at 1-800-FDA-1088 or www.fda/gov/medwatch. Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873 PI0690600202 Rev. 06/2017

Adverse event reports

Source: openFDA FAERS
4,305
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class III January 21, 2026 SUN PHARMACEUTICAL INDUSTRIES INC Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D. Ongoing
Class II January 30, 2019 LUPIN SOMERSET Failed Impurities/Degradation Specifications: Expansion of October 2018 recall due to elevated out of specification results for total impurities that have been chemically identified as oxidative degradation products of the fluocinolone active pharmaceutical ingredient. Terminated
Class II October 31, 2018 LUPIN SOMERSET Failed Impurities/Degradation Specifications:Out of specification result noticed for total impurities observed during stability analysis Terminated
Class III April 19, 2017 Novel Laboratories, Inc. Chemical Contamination Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0168-0059-60 0168-0059 Fougera Pharmaceuticals, LLC 60 mL in 1 BOTTLE (0168-0059-60) December 16, 1982
43386-069-60 43386-069 Lupin Pharmaceuticals,Inc. 1 BOTTLE in 1 CARTON (43386-069-60) / 60 mL in 1 BOTTLE September 2, 2015
51672-1365-2 51672-1365 Sun Pharmaceutical Industries, Inc. 1 BOTTLE in 1 CARTON (51672-1365-2) / 20 mL in 1 BOTTLE March 27, 2015
51672-1365-4 51672-1365 Sun Pharmaceutical Industries, Inc. 1 BOTTLE in 1 CARTON (51672-1365-4) / 60 mL in 1 BOTTLE March 27, 2015
0168-0059 0168-0059 Fougera Pharmaceuticals, LLC — December 16, 1982
43386-069 43386-069 Lupin Pharmaceuticals,Inc. — September 2, 2015
51672-1365 51672-1365 Sun Pharmaceutical Industries, Inc. — March 27, 2015

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.